News Wire

A mass shooting at a Florida high school that left 17 people dead has reopened a debate in Congress about loosening long-standing restrictions on Centers for Disease Control and Prevention (CDC) research into gun violence, according to an article in The Hill. Democrats have frequently railed against…
Less than one week after it scored approval from the FDA for Glatopa (glatiramer acetate injection), a generic version of Teva’s multiple sclerosis drug Copaxone, Novartis may be looking to sell off its generics subsidiary Sandoz, BioSpace reports. Citing unnamed sources “familiar with the matter,”…
To keep rising health care costs in check, many health insurers have adopted a strategy known as “step therapy,” a policy requiring patients to try cheaper drugs first—and find them to be ineffective—before approving pricier medication. However, some health care experts contend the approach,…
Aimmune Therapeutics, Inc., has announced that its peanut allergy drug met the main goal of an eagerly awaited late-stage study, sending its shares up 18% pre-market, Reuters reports. The positive trial data comes nearly four months after French drug developer DBV Technologies SA’s stick-on patch…
The FDA has approved an amantadine extended-release tablet (Osmolex ER, Osmotica Pharmaceutical) for the treatment of Parkinson’s disease and for the treatment of drug-induced extrapyramidal reactions in adults. Extrapyramidal symptoms are known side effects of many common medications. Osmolex ER…
The FDA has approved a new indication for durvalumab (Imfinzi, AstraZeneca)–– treating patients with unresectable stage III non–small–cell lung cancer (NSCLC) whose cancer has not progressed after treatment with chemoradiation. Durvalumab becomes the first treatment approved to reduce the risk…
Promising new findings in the treatment of plaque psoriasis, oral ulcers, and genital psoriasis have been reported at the 2018 American Academy of Dermatology Annual Meeting in San Diego. Risankizumab Outperforms Stelara More patients with plaque psoriasis treated with risankizumab (AbbVie/ Boehringer…
A federal judge in Delaware has overturned a jury’s verdict requiring Gilead Sciences to pay a record $2.54 billion because its hepatitis C drugs sofosbuvir (Sovaldi) and ledipasvir/sofosbuvir (Harvoni) infringed a patent held by rival Merck & Company, according to a Reuters report. The verdict had…
The flu-related deaths of 22 more children were reported during the week ending February 10, federal officials say, bringing the pediatric toll to 84 for this grim flu season. Nearly 20,000 people have been hospitalized so far, with weeks to go. Several of the childhood deaths occurred weeks earlier…
This year’s vaccine has been 36% effective against viruses that have made for a particularly trying flu season––but some age groups are receiving “no statistically significant protection,” according to interim estimates released by the Centers for Disease Control and Prevention (CDC). Vaccine…
The FDA has approved apalutamide (Erleada, Janssen Pharmaceutical Companies), the first treatment indicated for nonmetastatic, castration-resistant prostate cancer. “This approval is the first to use the endpoint of metastasis-free survival, measuring the length of time that tumors did not spread…
The FDA has permitted marketing of the first blood test to evaluate mild traumatic brain injury (mTBI), commonly referred to as concussion, in adults. The FDA reviewed and authorized the Banyan Brain Trauma Indicator (Banyan Biomarkers, Inc.) in less than six months as part of its Breakthrough Devices…
Prescription drug costs are expected to see the fastest annual growth among health care expenditures over the next decade, the Centers for Medicare and Medicaid Services (CMS) predicts, rising an average of 6.3% a year due to higher drug prices and more use of specialty drugs such as those for genetic…
New clinical decision support software designed to analyze computed tomography (CT) results may speed treatment by notifying providers of a potential stroke in their patients. The FDA has permitted marketing of Viz.AI Contact (Viz.AI), a computer-aided triage software application that uses an artificial…
Avelumab (Bavencio, Merck KGaA/Pfizer Inc.) did not improve overall survival compared with docetaxel in a phase 3 trial among patients with unresectable, recurrent, or metastatic non–small-cell lung cancer (NSCLC) whose tumors were positive for programmed death ligand-1 (PD-L1+) and whose disease…

Pages